RareCyte, Inc., a pioneering Life Sciences company renowned for its Precision Biology platforms, has announced the successful completion of a $20 million financing round aimed at bolstering its Orion™ Spatial Biology platform. This funding, sourced from a blend of new and existing investors, including Forest Road, Arboretum Ventures, and F-Prime Capital, underscores RareCyte’s commitment to…
Vertus Energy, a pioneering industrial biotech firm specializing in Waste-to-X solutions, has successfully raised €8.75 million in a Seed funding round to advance its innovative approach to managing bacteria behavior in biogas production. This funding marks a significant milestone for Vertus Energy as it strives to redefine waste treatment by converting it into valuable resources…
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a pioneering biopharmaceutical firm renowned for its innovative approach to severe ischemic diseases, has announced a significant milestone today. The company successfully finalized agreements for a private placement offering, securing $11.8 million in gross proceeds from accredited investors. This strategic funding round underscores DiaMedica’s commitment to advancing clinical and product…
Augustine Therapeutics, a pioneering biotechnology firm specializing in innovative therapies for neurodegenerative and cardiometabolic diseases, announced a significant milestone today with the successful completion of a EUR 17 million (USD 18.5 million) first closing of its Series A funding round. This financing, led by Asabys Partners and supported by Eli Lilly and Company and the…
TwoStep Therapeutics emerges as a beacon of hope in cancer treatment with the announcement of its official launch and the successful closure of a $6.5 million seed funding round led by NFX. Founded by CEO Caitlyn Miller and distinguished Stanford professors Jennifer Cochran, Ronald Levy, and Nobel Laureate Carolyn Bertozzi, TwoStep is set to revolutionize…
Foray Bioscience, a pioneering force in sustainable biotechnology, has announced a significant milestone with the successful closure of a $3 million seed funding round led by ReGen Ventures. This latest injection of capital, supported by prominent investors including The Engine Ventures and Susquehanna Sustainable Investments, underscores Foray’s commitment to reshaping the future of plant-based industries…
EpilepsyGTx, a pioneering biotechnology firm specializing in advanced gene therapies for focal refractory epilepsy, has announced a successful $10 million seed funding round. The financing, spearheaded by the UCL Technology Fund and bolstered by Health Technology Holding, marks a significant milestone in the company’s journey towards combating this challenging neurological disorder. Led by CEO Nicolas…
Vico Therapeutics, a pioneering clinical-stage genetic medicines company, has successfully closed its Series B funding round with a total investment of €65.8 million ($70.7 million). This financing round, led by Seroba and Kurma Partners, marks a significant milestone in Vico’s journey towards developing transformative therapies for severe neurological diseases. Vico Therapeutics specializes in antisense oligonucleotide…
Valneva SE has achieved a historic milestone with Health Canada’s approval of the world’s first chikungunya vaccine. Following its successful launch in the U.S. and pending European authorization, this decision underscores IXCHIQ®’s pivotal role in global healthcare strategy. Chikungunya, a mosquito-borne virus causing severe joint pain and fever, poses a significant public health threat with…
Since its inception, Ethris GmbH has been a trailblazer in mRNA technology, revolutionizing the biotech landscape with its innovative approach to respiratory and cardiovascular diseases. Founded on a vision of harnessing messenger RNA (mRNA) for therapeutic breakthroughs, Ethris has consistently pushed boundaries, drawing attention from investors and global biotech leaders alike. Breakthroughs and Strategic Growth…
